Aclaris Therapeutics Inc.

1.02+0.0336+3.41%Vol 5.82M1Y Perf -93.80%
Dec 6th, 2023 16:00 DELAYED
BID1.01 ASK1.02
Open1.08 Previous Close0.9864
Pre-Market- After-Market1.00
 - -  -0.02 -1.96%
Target Price
32.50 
Analyst Rating
Moderate Buy 2.00
Potential %
3.09K 
Finscreener Ranking
★★★★     53.33
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     57.62
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★+     56.09
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
2.39 
Earnings Rating
Strong Buy
Market Cap72.25M 
Earnings Date
14th Nov 2023
Alpha0.02 Standard Deviation0.39
Beta0.27 

Today's Price Range

0.99111.15

52W Range

0.590218.54

5 Year PE Ratio Range

-9.40-2.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
12.32%
1 Month
-82.00%
3 Months
-86.94%
6 Months
-89.62%
1 Year
-93.80%
3 Years
-73.63%
5 Years
-88.52%
10 Years
-

TickerPriceChg.Chg.%
ACRS1.020.03363.41
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
Financial StrengthValueIndustryS&P 500US Markets
12.60
13.00
0.04
0.00
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
48.60
-356.90
-353.50
-2 098.60
-
RevenueValueIndustryS&P 500US Markets
22.00M
0.33
-22.75
-
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.48-0.4114.58
Q02 2023-0.45-0.426.67
Q01 2023-0.44-0.424.55
Q04 2022-0.46-0.4110.87
Q03 2022-0.39-0.3023.08
Q02 2022-0.36-0.3113.89
Q01 2022-0.39-0.3120.51
Q04 2021-0.36-0.37-2.78
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.3918.75Positive
12/2023 FY-1.659.34Positive
3/2024 QR-0.3419.05Positive
12/2024 FY-1.1636.61Positive
Next Report Date-
Estimated EPS Next Report-0.48
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume5.82M
Shares Outstanding70.84K
Shares Float66.94M
Trades Count20.78K
Dollar Volume6.30M
Avg. Volume5.28M
Avg. Weekly Volume3.38M
Avg. Monthly Volume8.94M
Avg. Quarterly Volume3.53M

Aclaris Therapeutics Inc. (NASDAQ: ACRS) stock closed at 0.9864 per share at the end of the most recent trading day (a 0.39% change compared to the prior day closing price) with a volume of 1.92M shares and market capitalization of 72.25M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 60 people. Aclaris Therapeutics Inc. CEO is Neal Walker.

The one-year performance of Aclaris Therapeutics Inc. stock is -93.8%, while year-to-date (YTD) performance is -93.74%. ACRS stock has a five-year performance of -88.52%. Its 52-week range is between 0.5902 and 18.54, which gives ACRS stock a 52-week price range ratio of 2.39%

Aclaris Therapeutics Inc. currently has a PE ratio of -12.80, a price-to-book (PB) ratio of 5.02, a price-to-sale (PS) ratio of 49.44, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -33.44%, a ROC of -37.49% and a ROE of -40.70%. The company’s profit margin is -%, its EBITDA margin is -353.50%, and its revenue ttm is $22.00 Million , which makes it $0.33 revenue per share.

Of the last four earnings reports from Aclaris Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.48 for the next earnings report. Aclaris Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aclaris Therapeutics Inc. is Moderate Buy (2), with a target price of $32.5, which is +3 086.27% compared to the current price. The earnings rating for Aclaris Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aclaris Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aclaris Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 30.36, ATR14 : 0.30, CCI20 : -39.12, Chaikin Money Flow : 0.05, MACD : -1.06, Money Flow Index : 74.92, ROC : 11.43, RSI : 21.84, STOCH (14,3) : 83.07, STOCH RSI : 1.00, UO : 56.04, Williams %R : -16.93), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aclaris Therapeutics Inc. in the last 12-months were: Anand Mehra (Option Excercise at a value of $0), Balthaser Kevin (Buy at a value of $74 971), Balthaser Kevin (Sold 0 shares of value $0 ), Douglas J. Manion (Buy at a value of $50 278), Douglas J. Manion (Sold 0 shares of value $0 ), Gowen Maxine (Option Excercise at a value of $0), Humphries William (Option Excercise at a value of $0), James Loerop (Buy at a value of $99 994), James Loerop (Sold 0 shares of value $0 ), James Loerop (Sold 4 267 shares of value $59 272 ), Joseph Monahan (Sold 5 000 shares of value $65 311 ), Milano Vincent (Option Excercise at a value of $0), Molineaux Christopher (Option Excercise at a value of $23 603), Monahan Joseph (Option Excercise at a value of $0), Monahan Joseph (Sold 41 837 shares of value $512 603 ), Neal Walker (Sold 70 000 shares of value $1 104 479 ), Powell Andrew (Option Excercise at a value of $0), Reasons Bryan (Option Excercise at a value of $0), Schiff Andrew (Option Excercise at a value of $0), Walker Neal (Option Excercise at a value of $0), Walker Neal (Sold 129 240 shares of value $1 845 322 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (50.00 %)
10 (100.00 %)
9 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (50.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Strong Buy
1.00
Strong Buy
1.00

Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.

CEO: Neal Walker

Telephone: +1 484 324-7933

Address: 640 Lee Road, Wayne 19087, PA, US

Number of employees: 60

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

60%40%

 

TipRanks News for ACRS


News

Stocktwits